Trever Bivona, MD, PHD
Medical Oncology · San Francisco
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 12
- 2 carriers
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bivona’s office at (415) 353-7160 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A119835 · Current
Licensed to practise in California · since 2012 · expires 2027-11-30 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Medical Oncology
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 11 Part D prescriptions in 2014. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
$3,476 in 2025
| 2025 | 1 | 5 | $3,250 | $3,476 |
| 2024 | 3 | 8 | $8,663 | $8,995 |
| 2023 | 2 | 3 | $1,510 | $1,569 |
| 2019 | 5 | 23 | $9,800 | $13,819 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | None | $3,476 | 5 payments
|
See all 5 published payments
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-22 | None | $3,250 |
| E.R. Squibb & Sons L.L.C. | Travel · 2025-05-13 | None | $34 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-09 | None | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-25 | None | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-25 | None | $135 |
See earlier years (2024, 2023, 2019)
2024: $8,995
| Abbvie | None | $3,524 | 4 payments
|
| Daiichi Sankyo | None | $3,083 | 2 payments
|
| Genentech USA | None | $2,389 | 2 payments
|
2023: $1,569
| Gilead Sciences | Trodelvy | $819 | 2 payments
|
| Deciphera Pharmaceuticals | None | $750 | 1 payment
|
2019: $13,819
| AstraZeneca Pharmaceuticals LP | Tagrisso | $8,564 | 11 payments
|
| Array BioPharma | None | $4,654 | 9 payments
|
| Jazz Pharmaceuticals | None | $450 | 1 payment
|
| Novartis Pharmaceuticals | Mekinist | $141 | 1 payment
|
| Pfizer | Lorbrena | $11 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Daiichi Sankyo Company LTD · Evaluate the Combination Effects of Ds-1062a and Current Targeted Therapies in Clinical Use in Egfr Mutant and Alk Gene Rearrangement Positive Non-Small Cell Lung Cancer (Nsclc) Patients and To Invest · 2025 | Their institution | $93,184 |
Professional record
- NPI
- 1093861346
- Licence
- CA A119835, NY 242984California A119835: Current · expires 2027-11-30
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 1600 Divisadero Street, 4th Floor, Box 1674, San Francisco, CA, 94115
- NPI first listed
- 2007-01-26
- NPI last updated
- 2019-03-20
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1233 York Ave, New York, NY, 10065